Trial Outcomes & Findings for Servo-Ventilation In-lab PSG Evaluation (NCT NCT02808338)

NCT ID: NCT02808338

Last Updated: 2019-03-19

Results Overview

The Apnea Hypopnea Index is the number of the apneas and hypopneas during one hour of sleep. The average of these events over one night were compared during each overnight device use.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

25 participants

Primary outcome timeframe

4 nights

Results posted on

2019-03-19

Participant Flow

A multi-site study that accrued over 2016 and into the middle of 2017.

Participant milestones

Participant milestones
Measure
Screening
All participants that consented to the study were considered for the participant flow. 15 participants were randomized to participate in the overnight in lab PSG's, these overnights were randomized to 1 of 4 interventions for each of the 4 overnights. This randomization scheme resulted in a large number of device sequences.
Screening
STARTED
25
Screening
COMPLETED
15
Screening
NOT COMPLETED
10
Overnight In-lab Polysomonography
STARTED
15
Overnight In-lab Polysomonography
Modified Philips BiPAP ASV
13
Overnight In-lab Polysomonography
ResMed S7 VPAP Adapt
13
Overnight In-lab Polysomonography
Philips BiPAP AutoSV Advanced System One
12
Overnight In-lab Polysomonography
ResMed S9 VPAP Adapt
12
Overnight In-lab Polysomonography
COMPLETED
13
Overnight In-lab Polysomonography
NOT COMPLETED
2
Take Home Period
STARTED
13
Take Home Period
COMPLETED
13
Take Home Period
NOT COMPLETED
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Screening
All participants that consented to the study were considered for the participant flow. 15 participants were randomized to participate in the overnight in lab PSG's, these overnights were randomized to 1 of 4 interventions for each of the 4 overnights. This randomization scheme resulted in a large number of device sequences.
Screening
Screen Failure
10
Overnight In-lab Polysomonography
Withdrawal by Subject
1
Overnight In-lab Polysomonography
Reason not given
1

Baseline Characteristics

Servo-Ventilation In-lab PSG Evaluation

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Screening
n=20 Participants
All participants that consented to the study.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
10 Participants
n=5 Participants
Age, Categorical
>=65 years
10 Participants
n=5 Participants
Age, Continuous
65.3 years
STANDARD_DEVIATION 12.6 • n=5 Participants
Sex: Female, Male
Female
3 Participants
n=5 Participants
Sex: Female, Male
Male
17 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
20 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
Race (NIH/OMB)
White
20 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Region of Enrollment
United States
20 participants
n=5 Participants

PRIMARY outcome

Timeframe: 4 nights

Population: 1 participant was excluded because he did not meet the criteria to receive ASV.

The Apnea Hypopnea Index is the number of the apneas and hypopneas during one hour of sleep. The average of these events over one night were compared during each overnight device use.

Outcome measures

Outcome measures
Measure
Philips BiPAP AutoSV Advanced System One
n=12 Participants
Philips Bilevel Postitive Airway Perssure (BiPAP) AutoSV Advanced System One: Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
Modified Philips BiPAP ASV
n=13 Participants
Modified Philips BiPAP AutoServoventilation (ASV): This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
ResMed S7 VPAP Adapt
n=13 Participants
ResMed S7 Variable Positive Airway Pressure (VPAP) Adapt: This device is FDA approved and will be set to predetermined setting.
ResMed S9 VPAP Adapt
n=12 Participants
ResMed S9 VPAP Adapt: This device is FDA approved and will be set to predetermined setting.
Average Apnea Hypopnea Index Among Different Polysomnography Devices.
18.4 events per hour
Standard Deviation 23.0
25.4 events per hour
Standard Deviation 25
24.1 events per hour
Standard Deviation 25.4
19.2 events per hour
Standard Deviation 23.1

Adverse Events

Philips BiPAP AutoSV Advanced System One

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Modified Philips BiPAP ASV

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

ResMed S7 VPAP Adapt

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

ResMed S9 VPAP Adapt

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Take Home - Modified Philips BiPAP ASV

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Philips BiPAP AutoSV Advanced System One
n=12 participants at risk
The Bi-Level Positive Airway Pressure system will be used and will be configured with these settings. P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto Philips BiPAP AutoSV Advanced System One: Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
Modified Philips BiPAP ASV
n=13 participants at risk
The modified Philips BiPAP ASV will be configured with these settings P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto Modified Philips BiPAP ASV: This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
ResMed S7 VPAP Adapt
n=13 participants at risk
This is an FDA approved device and the following settings will be administered: EEP: 4 PSmin: 3 PSMax: 16 ResMed S7 VPAP Adapt: This device is FDA approved and will be set to predetermined setting.
ResMed S9 VPAP Adapt
n=12 participants at risk
This is an FDA approved device and the following settings will be administered: EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 20 Max Ramp: Off ResMed S9 VPAP Adapt: This device is FDA approved and will be set to predetermined setting.
Take Home - Modified Philips BiPAP ASV
n=13 participants at risk
After the overnight PSGs participants took home the Modified Philips BiPAP ASV for 30 days.
Cardiac disorders
EKG abnormalities
0.00%
0/12 • 40 days
0.00%
0/13 • 40 days
7.7%
1/13 • Number of events 1 • 40 days
0.00%
0/12 • 40 days
0.00%
0/13 • 40 days
Cardiac disorders
Paroxysmal Supraventricular Tachycardia
8.3%
1/12 • Number of events 1 • 40 days
0.00%
0/13 • 40 days
0.00%
0/13 • 40 days
0.00%
0/12 • 40 days
0.00%
0/13 • 40 days
Nervous system disorders
seziure
0.00%
0/12 • 40 days
0.00%
0/13 • 40 days
0.00%
0/13 • 40 days
0.00%
0/12 • 40 days
7.7%
1/13 • Number of events 1 • 40 days
Cardiac disorders
non-sustained ventricular tachycardia
0.00%
0/12 • 40 days
0.00%
0/13 • 40 days
7.7%
1/13 • Number of events 1 • 40 days
0.00%
0/12 • 40 days
0.00%
0/13 • 40 days
Cardiac disorders
Supraventricular Tachycardia
0.00%
0/12 • 40 days
0.00%
0/13 • 40 days
7.7%
1/13 • Number of events 1 • 40 days
0.00%
0/12 • 40 days
0.00%
0/13 • 40 days

Additional Information

Clinical Operations Manager

Philips

Phone: 14125423669

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place